Roche's New Lung Cancer Drug Wins Head-to-Head Trial, Extending Median Survival by 5.7 Months
nashnova research
Roche's divarasib extended median overall survival by 5.7 months and cut the risk of death by 44% in a Phase III head-to-head trial against Amgen's and Bristol Myers Squibb's existing KRAS G12C-targeted therapies — redrawing the competitive line for this mutation class.
What did this trial actually prove?
The Phase III Krascendo 1 trial enrolled 338 previously treated patients with advanced KRAS G12C-mutant non-small cell lung cancer. The control arm used Amgen's sotorasib and BMS's adagrasib.
The divarasib arm reached a median overall survival of 17.7 months vs. 12.0 months for controls; median progression-free survival rose from 5.7 months to 9.8 months — both primary endpoints improved.
This means → this is not an indirect comparison or a surrogate-endpoint inference. It is a direct, same-target head-to-head survival win — the highest level of clinical evidence.
How did the side-effect profile compare?
Serious treatment-related adverse events hit 7.8% in the divarasib arm vs. 15.2% in controls — roughly half the rate.
Treatment discontinuation due to side effects: 4.8% for divarasib, 11.7% for controls.
In plain terms = the drug is both more effective and less toxic. Patients stay on treatment longer, which itself reinforces the survival advantage.
What makes this drug's mechanism different?
Divarasib is a covalent inhibitor — a drug that locks onto the mutant KRAS G12C protein and holds it in its inactive state, blocking downstream growth signals.
Pre-clinical data show higher potency and selectivity than existing drugs in the same class.
This means → the target is not new; the advance is a more precise lock on the same target, and that precision is where both the efficacy and safety gains originate.
How large is the commercial opportunity?
Bloomberg consensus estimates project divarasib annual sales above CHF 1 billion (roughly $1.3 billion) by 2032.
Roche posted Q3 sales of CHF 16.13 billion, up 7% at constant exchange rates, but its mature product Xolair underperformed due to lower-priced competition.
This reflects Roche's need for a fresh growth engine to offset aging-product headwinds — divarasib fits that gap.
Where do the follow-on trials point?
Krascendo 2 tests divarasib combined with Merck's Keytruda as a first-line, chemo-free regimen for untreated advanced lung cancer.
Krascendo 3 studies divarasib as post-surgery adjuvant therapy to reduce recurrence in operable lung cancer.
In plain terms = the current win covers patients who have already failed other drugs. If the next two trials succeed, the eligible population expands from second-line to first-line and post-surgical settings — potentially more than doubling the addressable market — and that expansion is the main driver behind analysts' long-term sales forecasts.
市场有风险，内容仅供研究参考，不构成投资建议。